Free tool
FAERS Monitor: Welireg
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215383 or its brand name (Welireg, Belzutifan). Reports on generic versions are filed under their own applications.
Reports
1,777
Serious
1,224
69% of reports
Hospitalization
727
Death reported
167
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaemia329
- malignant neoplasm progression262
- hypoxia174
- fatigue129
- death80
- dyspnoea70
- diarrhoea66
- haemoglobin decreased65
- off label use65
- oxygen saturation decreased61
- nausea59
- therapy interrupted57
- drug ineffective52
- hospitalisation51
- pneumonia41
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 39 |
| 2022 | 315 |
| 2023 | 388 |
| 2024 | 179 |
| 2025 | 234 |
| 2026 | 622 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,382 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoxiaSignal | 174 | 58.8 | 51.0 | 9,792 |
| malignant neoplasm progressionSignal | 262 | 30.4 | 27.1 | 7,426 |
| anaemiaSignal | 329 | 20.5 | 18.5 | 6,112 |
| oxygen saturation decreasedSignal | 61 | 12.9 | 10.0 | 656 |
| therapy interruptedSignal | 57 | 9.4 | 7.3 | 423 |
| haemoglobin decreasedSignal | 65 | 7.5 | 5.9 | 361 |
| hospitalisationSignal | 51 | 3.9 | 3.0 | 109 |
| fatigue | 129 | 2.0 | 1.7 | 62 |
| pneumonia | 41 | 1.5 | 1.1 | 6 |
| dyspnoea | 70 | 1.5 | 1.2 | 10 |
| diarrhoea | 66 | 1.2 | 1.0 | 2 |
| death | 80 | 1.1 | 0.9 | 1 |
| nausea | 59 | 0.9 | 0.7 | 1 |
| off label use | 65 | 0.9 | 0.7 | 1 |
| drug ineffective | 52 | 0.5 | 0.4 | 33 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.